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Abstract
Background: Obesity has been related with higher Gleason grade and worse prognosis. Increasing proportion of Gleason 
pattern 4 or 5 is a critical factor for biochemical recurrence, progression and mortality. The endocrine activity of visceral fat could 
be responsible of the differentation of the prostatic malignant cell towards a more aggressive fenotype. The aim of our study was to 
correlate Body Mass Index with the presence of Gleason pattern 4 or higher at biopsy. 
Materials and Methods: Consecutive patients with positive prostate biopsy were included. A transrectal prostate biopsy 
procedure with 12 cores, was performed. All tissue samples were reviewed.
Results: Out of 135 patients diagnosed with prostate cancer at biopsy, a Gleason. pattern 4 or 5 was evident in 57 (42%) 
patients, while it was not detected in 78 (58%). The statistical analysis did not demonstrate a correlation between the histological 
expression of Gleason pattern 4 or 5 in the bioptic specimens and the BMI class. Conclusion: Although high risk prostate cancer 
has been reported more frequent in patients with higher BMI, in our experience, no significant correlation between BMI and Gleason 
patterns 4 and 5 at biopsy was detected. Other factors responsible for the worse prognosis and the more aggressive behavior of 
prostate tumors in obeses should be investigated.
Keywords: BMI; Gleason grade; Obesity; Prostate Biopsy; Prostate 
cancer
Introduction
Several studies investigated the correlation between obesity and 
prostate cancer with inconsistent results. A lower prostate cancer 
incidence has been reported in obese men aged 65 or less [1,2]. On 
the other hand, a fair evidence emerges that prostate tumors in obese 
men have high-grade disease, more aggressive behavior and worse 
prognosis [3,4]. Body Mass Index (BMI), is a worldwide adopted and 
cost-effective method to measure overall adiposity, although is it does 
not account for body mass composition and fat tissue distribution.
Higher BMI is associated with lower PSA (Prostatic Specific 
Antigen) plasmatic levels, that are 7% lower in overweight patients 
(BMI:25–29), 14% lower in obese patients (BMI:30–35), and 18% lower 
in severely obese patients (BMI>35) [5]. Consequently, a detection bias 
might be responsible of later diagnosis and more advanced T-stage and 
Gleason grade [6,7]. 
Gleason score is the most widely adopted grading system for 
prostate carcinoma. It is based on the sum of two patterns (or grades) 
ranging from 1 to 5, with 5 having the worst prognosis. The first number 
is the grade of the most common tumor pattern, the second number 
is the grade of the second most common pattern. The Gleason Score 
ranges from 2 to 10, with 10 having the worst prognosis.
In few studies, obesity has been related with higher Gleason grade 
and when compared with normal weight population [8]. Increasing 
proportion of Gleason pattern 4 and/or 5 is a critical factor in predicting 
biochemical recurrence, progression and mortality of prostate cancer. 
The endocrine activity of visceral fat could be responsible of an 
increase of biological factors interacting with the differentiation of 
the prostatic malignant cell towards a more aggressive fenotype. High 
plasmatic levels of adipokines have been related to higher Gleason scores 
in obese patients. Leptin stimulates prostate cell proliferation, migration, 
growth factor expression and androgen resistance. Adiponectin plays 
opposite role. Prostate gland is exposed both to circulating adipokines 
and to those locally produced by periprostatic fat. It is plausible that 
abnormal levels of adipokines, interacting with androgens and other 
factors might select cells with a higher aggressiveness, in an early phase 
of metabolic syndrome when obesity is not yet relevant.
If a higher incidence of Gleason pattern 4 at biopsy would 
be confirmed in obese and overweight men compared to normal 
population, this finding would explain their worse prognosis suggesting 
the need for more aggressive diagnostic approach not delaying biopsy 
and adopting more extensive bioptic templates.
The aim of our study was to correlate obesity, measured by Body 
Mass Index (BMI), with the presence of Gleason pattern 4 or higher 
at biopsy.
Materials and Methods
Consecutive patients with positive prostate biopsy performed for 
palpable prostate nodule and/or elevated PSA levels were entered in 
our study. A written informed consent was obtained in all patients. 
BMI was adopted to classify patients according to obesity. Patients 
were divided into four categories according to BMI as follows: 16–19,9 
(underweight), 20,0–24,9 (normal weight), 25,0–29,9 (overweight) and 
≥ 30,0 (obese). 
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A transrectal prostate biopsy procedure with 12 cores, was 
performed in all patients. 
The number of cores was increased in case of re-biopsy (18-24 cores 
or more). 
All the specimens were reviewed by an expert pathologist.
Statistics: The statistical analysis was conducted with Fisher’s exact 
test for Gleason pattern 4 (< 4 or ≥ 4) and BMI for single weight class. 
The Pearson’s Chi-squared test with Yates’ continuity correction was 
used for aggregate BMI classes. A P value of <0.05 was considered 
statistically significant.
Results
Out of 164 patients diagnosed with prostate cancer at biopsy, 29 
(17.7%) were excluded from the study. Particularly, ASAP (Atypical 
Small Acinar Proliferation) or PIN (Prostatic Intraepithelial Neoplasia) 
was diagnosed in 5, a single microscopic positive foci with undetermined 
Gleason score in 6 and a biopsy with a low number of bioptic cores, 
between 4 and 6, not evaluable for the aims of our study was obtained 
in the remaining 18 patients.
Of the 135 evaluable patients, 20 (14,81%) patients had a previous 
negative biopsy. 
Patients characteristics are reported in Table 1.
The median age was 71 years (range 49-76). The median BMI 
was 26.8 (17.5-37.4). Only 2 patients (1,48%) were underweight. 38 
(28,15%) patients had normal weight (median BMI 23,15), 61 (45,18%) 
were overweight (median BMI 27,3) and 34 (25,18%) were obese 
(median BMI 31,7)
Median PSA was 10,55 ng/ml (range 0,41-1339). A prostate nodule 
was palpable in 55 (40,7%) patients. The median prostate volume 
was 40,4 cc. (Table 1). A Gleason pattern 4 or 5 was evident in 57 
(42,2%) patients, while it was not detected in 78 (57,8%) patients. The 
distribution of Gleason patterns according to BMI classes are given in 
Figure 1.
The statistical analysis did not demonstrate a correlation between 
the histological expression of Gleason pattern 4 or 5 in the bioptic 
specimens and the BMI class (p=0,79). Even combining different BMI 
classes, normal weight plus overweight men versus obese (p=0,64); 
normal weight versus overweight plus obese men (p=0,93), no 
statistically significant relation emerged (Table 2).
Discussion 
Biological and clinical evidence supports the presence of Gleason 
patterns 4 and 5 as relevant predictors of aggressive prostate cancer [9]. 
The patients harboring prostate cancer showing Gleason patterns 4 or 
5 have a poorer prognosis and need early diagnosis and treatment. To 
select for biopsy procedure patients at risk for aggressive tumor avoiding 
diagnosis of indolent, low-risk prostatic cancer is a major challenge for 
the urologic and scientific community. 
The distinct behavior between pattern 3 and pattern 4/5 prostatic 
tumors could be the result of different developmental pathways, 
although up today is unclear which molecular changes are involved 
[10]. Presumably, environmental and hormonal factors can induce 
additional oncogenic mutations in genetically susceptible and instable 
prostate cells. When examined by stage and grade, obese men are more 
likely to be diagnosed with high grade disease [3,7].
A link between high grade prostate cancers and lower serum 
testosterone concentrations in obese patients has been suggested 
by many Authors [8,11]. Moreover abnormal levels of adipokines, 
biological factors with relevant carcinogenetic activity produced by the 
visceral fat tissue, may promote the progression of latent or microscopic 
low grade prostate tumors to high grade clinically significant cancers 
[12,13]. Freedland and coll in 2008 [14] and more recently De Nunzio 
and coll [3] reported a frequent incidence of high Gleason grade at 
biopsy. This finding has important clinical implications since the 
treatment choice is mainly based, although not exclusively, on Gleason 
grade.
The aim of our study was to confirm the data of literature reporting 
higher Gleason grade, with prevalence of pattern 4 and 5, in obese 
Figure 1: Correlation between the expression of Gleason pattern 4 and 5 and 
BMI: 
No difference emerges in Gleason distribution in relation with the BMI.
ENTERED PATIENTS
EVALUABLE PATIENTS
164
135
MEDIAN AGE (years) 71 (49-86)
BMI CLASSES
underweight 2 (1.48%)
normal weight 38 (28.15%)
over weight 61 (45.18%)
obese 34 (25.18%)
MEDIAN BMI (Kg/m2) 2226.8 (17.5-37.4)
underweight 18.13
normal weight 23.15
over weight 27.3
obese 31.7
MEDIAN PSA (ng/ml) 10.5 (0.41-1339)
POSITIVE DRE 55 (40.7%)
MEDIAN PROSTATE VOLUME (CC) 40.4 (18-24)
PREVIOUS BIOPSY 20 (14.81%)
Table 1: Patients’ characteristics and their distribution according BMI classes and 
median BMI.
EVALUABLE PATIENTS 135
Gleason pattern  4 or 5 57 (42.2%)
Gleason patterns 4/5 and BMI p=0.79
Normal vs Overweight + Obese p=0.64
Normal + Overweight vs Obese p=0.93
Table 2: Correlation between BMI classes and the occurrence of Gleason patterns 
4 and  5 prostate tumors.
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patients and to investigate the relation between BMI and histology at 
prostate biopsy. If this was the case, a particular attention should be given 
to patients with higher BMI and a clinical suspect of prostate cancer. 
BMI might be considered together with the other prognostic factors 
suggesting the need for prostate biopsy. An increased number of biopsy 
cores has been advocated by some Authors in obese and overweight 
men due to an increased difficulty and delay in cancer detection. We 
included consecutive patients with a positive prostate biopsy for cancer. 
Mean PSA was 10 ng/ml, median age 71 years and, noteworthy, almost 
half of the patients was overweight and more than 20% obese. This is, 
nowadays, a common finding in everyday clinical practice, in patients 
with a positive prostate biopsy when you are not selecting for radical 
treatments [15]. In our experience no statistically significant relations 
was found between patients’ BMI and the distribution of Gleason 
patterns 4 and 5. Consequently, we cannot support BMI as a predictive 
factor of high grade disease suggesting the need for immediate prostate 
biopsy when a cancer is clinically suspected. A main bias of our study is 
the limited patients’ number not permitting data stratification according 
to stage and PSA levels. On the other hand, unselected consecutive 
patients of everyday clinical practice, undergoing biopsy for different 
clinical queries, were included, giving a practical value to our results. 
Since more than 70% of our patients were overweight or obese, our 
negative results may not have been due to a lack of association between 
BMI and Gleason pattern 4 or 5, but rather to a homogeneous study 
population. It must be argued that many factors other than Gleason 
grade might be responsible of the poor outcome related to high BMI.
Conclusion
Most of the patients undergoing prostate biopsy in western 
countries are overweight or obese. Although high risk prostate cancer 
has been reported to be more frequent in patients with higher BMI, 
in our experience, no significant correlation between BMI and the 
expression of Gleason patterns 4 and 5 at biopsy was detected. Thus, 
BMI cannot be considered a prognostic factor for high grade disease to 
select patients for prostate biopsy. Other biological and clinical factors 
could be responsible of the aggressive behavior of the prostate tumors 
in overweight and obese patients and should be the object of future 
investigations.
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